Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.18)
# 2,860
Out of 5,131 analysts
111
Total ratings
40.82%
Success rate
-2.9%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Buy | $220 → $230 | $196.52 | +17.04% | 22 | Feb 9, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $14.70 | +165.31% | 5 | Jan 6, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $36 | $31.91 | +12.82% | 5 | Jan 5, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.50 | +182.35% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $124.12 | +32.13% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.57 | +292.16% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.37 | +617.30% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $4.18 | +1,048.33% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $5.81 | +158.18% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $4.72 | +472.03% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.40 | +252.94% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.58 | +4,963.29% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.03 | +49.80% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $11.36 | +1,220.42% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $33.98 | - | 2 | Jan 31, 2017 |
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $220 → $230
Current: $196.52
Upside: +17.04%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $14.70
Upside: +165.31%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $28 → $36
Current: $31.91
Upside: +12.82%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.50
Upside: +182.35%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $124.12
Upside: +32.13%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.57
Upside: +292.16%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.37
Upside: +617.30%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $4.18
Upside: +1,048.33%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $5.81
Upside: +158.18%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $4.72
Upside: +472.03%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.40
Upside: +252.94%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.58
Upside: +4,963.29%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.03
Upside: +49.80%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $11.36
Upside: +1,220.42%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $33.98
Upside: -